1. The EFSA 800 mg Threshold: What It Actually Means

EFSA's 2018 scientific opinion reviewed all available human evidence on green tea catechins and hepatotoxicity. The panel concluded that EGCG doses at or above 800 mg/day from concentrated supplement form were associated with elevated liver enzyme markers (ALT, AST) in a statistically meaningful number of cases. Below this threshold, no consistent signal of liver damage was observed.

Two critical qualifications are often omitted when this number is cited. First, the 800 mg threshold applies specifically to supplement-form EGCG — concentrated extracts delivered as capsules or tablets, typically taken on an empty stomach. The panel explicitly noted that green tea beverages consumed in traditional patterns had not produced comparable hepatotoxic signals, even at similar total EGCG intakes.

Second, the mechanism of concern is not cumulative toxicity but acute peak concentration. The liver damage cases in the literature were clustered around scenarios producing abnormally high Cmax values: large bolus doses, fasting administration, and concentrated extract formulations designed for rapid absorption.

2. The Matcha Math: How Many Cups to Reach 800 mg

A standard matcha serving uses approximately 2 g of powder. Depending on grade and origin, this delivers roughly 100 mg of EGCG per serving (the range spans approximately 60–140 mg, with ceremonial grades typically in the 80–120 mg range).

Simple arithmetic places the EFSA threshold at approximately 8 servings per day — or about 13 g of matcha powder. In practical terms, this means 6–8 bowls of koicha-strength matcha or 8–10 bowls of usucha, consumed across a single day.

For the vast majority of matcha drinkers — consuming 1–3 servings per day — total EGCG intake remains well below the threshold. The risk zone begins at consumption patterns that are far outside traditional or even enthusiast norms.

3. The Fasting NOAEL Drop: When the Same Dose Becomes Dangerous

The most important insight from the EFSA review is not the 800 mg number itself but the dramatic difference between fed-state and fasted-state pharmacokinetics. When EGCG is consumed on an empty stomach, the no-observed-adverse-effect level (NOAEL) drops by approximately one order of magnitude — roughly a 10-fold reduction.

The mechanism is straightforward. Without food in the stomach to slow gastric emptying and provide binding substrates, EGCG is absorbed rapidly and completely. The resulting Cmax spike — the peak plasma concentration — can reach levels that overwhelm hepatic detoxification capacity. The liver's conjugation pathways (glucuronidation, sulfation, and methylation) become saturated, and unmetabolized EGCG accumulates to cytotoxic concentrations.

This is why supplement-form EGCG has produced hepatotoxicity signals while traditional tea drinking has not: supplements are often taken on an empty stomach in concentrated bolus form, producing Cmax values that traditional beverage consumption never approaches.

4. Wagashi as Pharmacokinetic Buffer

The Japanese tea ceremony tradition of serving wagashi (traditional tea sweets) before or alongside matcha is often discussed in aesthetic or cultural terms. But from a pharmacokinetic perspective, it functions as an elegant absorption buffer.

Wagashi are typically composed of rice flour, bean paste (anko), and sugar — a combination of carbohydrates, protein, and fat that performs several pharmacokinetically relevant functions. The food mass slows gastric emptying, extending the absorption window and reducing the Cmax spike. The sugars and starches provide additional binding substrates for EGCG in the gastrointestinal tract, further attenuating the rate of absorption.

Whether this was the original intent of the wagashi-matcha pairing is unknowable. But the functional result is clear: consuming matcha with food — particularly carbohydrate-rich food — converts a potentially steep Cmax spike into a gentler, broader absorption curve. The total EGCG absorbed may be similar, but the peak concentration is substantially lower, and it is peak concentration that drives hepatotoxic risk.

5. Casein Binding: The Matcha Latte Trade-Off

Milk-based matcha preparations introduce another pharmacokinetic variable: casein protein binding. Casein, the primary protein in cow's milk, has a strong affinity for EGCG and other catechins. When matcha is prepared as a latte, a significant fraction of the EGCG binds to casein in the cup before it ever reaches the gastrointestinal tract.

This binding reduces the bioavailability of free EGCG. Studies suggest that milk addition can reduce catechin absorption by 20–40%, depending on the milk-to-matcha ratio and protein content. From a safety perspective, this is actually protective — it further reduces the Cmax that the liver must process. From a bioactivity perspective, it means that matcha lattes deliver less of the functional catechin payload than the same amount of matcha prepared with water alone.

This is a trade-off, not a deficiency. For individuals consuming multiple matcha servings per day, the casein buffer provides an additional safety margin. For those seeking maximum catechin bioactivity from a single serving, water-based preparation is preferred.

6. Thermal Stability: EGCG Survives Heat

A common concern among matcha users is whether hot water or baking destroys EGCG. The evidence is reassuring. EGCG retains greater than 80% of its structural integrity at temperatures up to 200°C in dry conditions, and thermal degradation in aqueous solution at typical brewing temperatures (70–85°C) is minimal over the time scales relevant to matcha preparation.

This means that matcha in baked goods, hot lattes, and standard whisked preparations retains the vast majority of its catechin content. The primary degradation pathway for EGCG in food systems is not thermal but oxidative — exposure to air and light over extended periods causes epimerization and polymerization. Proper storage (sealed, dark, cool) matters far more than preparation temperature.